Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age50-60
SponsorCairo University

About this trial

This study will be conducted to investigate the effect of DASH diet and Progressive muscle relaxation on cardiovascular risks in postmenopausal women.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

The participant's ages will be ranged from 50- 60 years old.

Their body mass index will be ranged from 30-35 kg/m2.

All women are hypertensive at least one year postmenopause.

Their scores in perceived stress scale will be ranged from 14-40.

Disqualifiers

Women with systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100mmHg.

Women who have other known causes of hypertension, such as renal diseases.

Women who are using sedatives or tranquilizer or antidepressant drugs.

Trial design

Design model

Parallel

Treatments tested in this trial

  • DASH diet

    Dietary supplement

    The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.

  • Progressive muscle relaxation

    Other intervention

    The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.

  • Anti hypertensive drugs

    Drug

    All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician

Treatment groups

90 Participants
are divided into 3 treatment groups
Group A: DASH diet groupExperimental treatment 2 interventions
Group B: Progressive muscle relaxation groupExperimental treatment 2 interventions
Group C: DASH diet and progressive muscle relaxation groupExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Systolic blood pressure

A sphygmomanometer will be used to measure systolic blood pressure (mmHg) for all participants in all groups before and after the treatment program

Time frame
3 months
2

Diastolic blood pressure

A sphygmomanometer will be used to measure systolic blood pressure (mmHg) for all participants in all groups before and after the treatment program

Time frame
3 months
3

Low density lipoprotein

Blood analysis will be used to measure level of low-density lipoprotein (mg/dl) for all participants in all groups before and after the treatment program. Its normal value is less than 100 mg/dl.

Time frame
3 months
4

High density lipoprotein

Blood analysis will be used to measure level of high-density lipoprotein (mg/dl) for all participants in all groups before and after the treatment program. Its normal value is from 40 to more than 60 mg/dl.

Time frame
3 months

Secondary outcomes

1

Stress measurement

Perceived stress scale (PSS) will be used to assess the degree of stress for all participants in all groups before and after the treatment program.The questions in the PSS ask about feelings and thoughts during the last month. In each case, respondents are asked how often they felt a certain way. Scoring: PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 items scale can be made from questions 2, 4, 5 and 10 of the PSS 10 items scale. The higher the total score, the higher the perceived stress level.

Time frame
3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.